Jansitin Duo

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jansitin Duo, is a Biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control through reduced hepatic glucose production and enhanced insulin secretion.

GNH USA supplies Jansitin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets and ensuring product quality through stringent manufacturing and distribution standards.

Jansitin Duo combines metformin and sitagliptin to address hyperglycemia in type 2 diabetes. - Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. - Inadequate control on metformin monotherapy: provides additional glucose‑lowering effect. - Adjunct to other antidiabetic agents: enhances efficacy of combination therapy in adults.

Like all antidiabetic medicines, Jansitin Duo may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring immediate medical attention. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute abdominal pain with elevated enzymes. - Allergic reactions: rash, pruritus, or angioedema.

Before prescribing Jansitin Duo, clinicians should evaluate patient-specific factors and follow safety recommendations. - Renal function: assess creatinine clearance and adjust use in moderate to severe impairment. - Hepatic disease: avoid in patients with significant liver dysfunction due to lactic acidosis risk. - Cardiovascular status: monitor for heart failure, as metformin may exacerbate symptoms. - Concomitant medications: review for drugs that affect renal clearance or increase hypoglycemia risk. - Pregnancy and lactation: use only if benefits outweigh potential risks, after professional evaluation. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Jansitin Duo can interact with several medicines; understanding the interaction level helps manage safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction, increasing metformin accumulation. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma concentrations. - Insulin or sulfonylureas: combined use may cause severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may enhance metformin‑related lactic acidosis risk. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Rifampin: may reduce sitagliptin efficacy by increasing its metabolism. - Oral corticosteroids: can elevate blood glucose, requiring dose adjustments.